Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

This publication has 28 references indexed in Scilit:

• Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer
  New England Journal of Medicine, 2010
• Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
  Journal of Clinical Oncology, 2009
• Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
  Journal of Clinical Oncology, 2008
• Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer
  Journal of Clinical Oncology, 2007
• Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
  Annals of Oncology, 2006
• Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
  Journal of Clinical Oncology, 2005
• Adjuvant Docetaxel for Node-Positive Breast Cancer
  New England Journal of Medicine, 2005
• Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
  Journal of Clinical Oncology, 2003
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
  Proceedings of the National Academy of Sciences, 2001
• Polychemotherapy for early breast cancer: an overview of the randomised trials
  The Lancet, 1998